Skip to main content

Search

Reset all filters
307 Result(s)
Sort by

China pioneers biosecurity report against ASF

China pioneers biosecurity report against ASF

Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Generalized pustular psoriasis at EADV

Generalized pustular psoriasis at EADV

Dr. Emmanuelle Clerisme-Beaty reflects on the latest developments for generalized pustular psoriasis at this year’s virtual EADV congress
Stem cells a new frontier

Stem cells a new frontier

Stem cells may be a game changer for the development of new veterinary treatments. Read this story to find out why.
COVID-19 IMI2–Call 21

COVID-19 IMI2–Call 21

CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.
Our Vision

Our Vision

At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
SIRPα Cancer Immunology Research

SIRPα Cancer Immunology Research

Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Collaboration to fight NCDs

Collaboration to fight NCDs

70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Purevax®

Purevax®

Purevax® is the only fully adjuvant-free feline vaccine range.
Targeting Tumor Stroma

Targeting Tumor Stroma

Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
Saving Stroke Patients around the world

Saving Stroke Patients around the world

Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
Bees and biodiversity

Bees and biodiversity

At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
COVID-19: Research Update

COVID-19: Research Update

Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19
Code of Conduct

Code of Conduct

Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
GPP Interview with Professor Barker

GPP Interview with Professor Barker

An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Championing novel science

Championing novel science

Dr. Vikas Mohan Sharma announces FDA fast-track designation for BI 1358894 as potential treatment for Borderline Personality Disorder.
Prevention of Schizophrenia

Prevention of Schizophrenia

Can schizophrenia be prevented?That’s what investigators are hoping to find out, according to scientists attending the American College of Neuropsychopharmacology (ACNP) in Orlando, Florida.[node:body][node:title]